trade name repatha monoclonal antibody immunotherapy medication treatment hyperlipidemia evolocumab fully human monoclonal antibody inhibits proprotein convertase subtilisinkexin type protein targets ldl receptors degradation inhibition thereby enhances livers ability remove ldlc often colloquially referred bad cholesterol evolocumab designed bind inhibit binding ldl receptors liver surface absence ldl receptors surface liver cells remove ldlc injection site reactions redness pain common reported approximately concerns mortality rate underreporting fourier study attracted controversy amgen submitted biologics license application bla evolocumab fda august fda approved evolocumab injection august patients unable get ldl cholesterol control current treatment european commission approved july evolocumab received approval health canada september amgen reported approval health canada press release september results fourier trial published march regeneron pharmaceuticals amgen filed patent protection monoclonal antibodies companies ended patent litigation us march district court found regenerons drug alirocumab infringed amgens patents amgen requested injunction barring regeneron sanofi marketing alirocumab granted january judge gave regeneron sanofi days appeal injunction went several years litigation patent dispute regeneron amgen docketed scotus marchapril numerous legal commentators surprised scotus decision considering existing trend review patent cases united states court appeals federal circuit since court created assure uniformity patent law among federal courts question us supreme court whether enablement governed statutory requirement specification teach skilled art make use claimed invention whether must instead enable skilled art reach full scope claimed embodiments without undue cumulatively identify make nearly embodiments invention without substantial time effort commentators believe scotus took case significance legal question deemed comparable impact ksr v teleflex issued amgens patents socalled functional genus claim defines antibody epitope specific target binds although amgen discover target antigen antigen patented product nature ie discovered rather invented however amgen able convince uspto issue patent broadly claims yetunmade antibodies high affinity discovered antigen although many potential problems functional genus claims lower courts invalidated broad amgens claims based patent requirements sufficiency disclosure purposivism justification disallowing broad poorlyenabled claims allow pharmaceutical companies develop potentially better drugs target receptor however drawback narrow interpretation resulting reluctance antigen discoverers share finding world early disclosure would prevent reaping maximum profits discovery could obtain developing multiple medications keeping secret many years however dilemma unique biologics pharmaceuticals since purpose patent system provide incentive earlier disclosure gambling game fromdiscoverytomarket necessarily reward every participant according contribution encourages discovers inventors play gambling game cost per year one article calculated per qualityadjusted life year qaly meet generally accepted costbenefit thresholds authors calculated annual cost would meet acceptable per qaly october maker drug amgen announced cut price drug date cost per httpsenwikipediaorgwikievolocumab